TC
GEVA

TFS Capital’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

TFS Capital’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-9,284
Closed -$589K – 1820
2013
Q3 		$589K Buy
+9,284
New +$457K 0.03% 797

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TFS Capital's GEVA Position: Q4 2013 in Review

TFS Capital sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q4 2013, closing a stake of 9,284 shares — an estimated $589K sold.

TFS Capital first reported a position in GEVA in Q3 2013 and held it in 1 quarter. The position peaked at $589K in Q3 2013. 84 funds tracked by Wall St. Rank hold GEVA as of Q4 2013.

  • TFS Capital reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q4 2013 after selling out during the quarter.
  • TFS Capital sold 9,284 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q4 2013, an estimated $589K.
  • TFS Capital first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2013 and held it in 1 quarter.
  • TFS Capital's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $589K in Q3 2013.
  • 84 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q4 2013.

Based on TFS Capital's 13F filing for Q4 2013, filed 7 Feb 2014.